RESEARCH ARTICLE

Role of pharmacogenetics and clinical parameters on nevirapine plasma concentration among HIV-1 patients receiving Antiretroviral Therapy in Kenya [version 1; peer review: 2 not approved]

Mungiria Juster¹, Lucy Gitonga¹, Moses Muraya¹, John Mwaniki², Musa Ngayo²

¹Department of Biological Sciences, Chuka University, P. O. Box 109-60400, Chuka, Kenya
²Centre for Microbiology Research, Kenya Medical Research Institute, P.O. Box 54840, 00200, Nairobi, Kenya

Abstract

Background: Patients' clinical outcomes and pharmacogenetic factors are important predictors of nevirapine (NVP) plasma concentration. This study evaluated the association of socio-demographic factors and Cytochrome P450 2B6 (CYP2B6) polymorphisms with NVP plasma concentrations among patients receiving antiretroviral therapy (ART) treatment in western and coastal Kenya.

Methods: Blood samples were collected from 377 consenting HIV adult patients receiving an NVP-based first-line ART regimen. A detailed sociodemographic questionnaire was administered. NVP plasma concentration was measured by liquid chromatography - tandem mass spectrometry (LC-MS/MS). CYP2B6 c.516 G>T rs3745274 and c.983T>C genotypes were evaluated using real-time polymerase chain reaction. HIV drug resistance mutations were detected using an in-house genotypic assay.

Results: The patients' mean age was 41.6 (SD ± 11.5) years and the majority (59.2%) were female. The mean duration of ART was 5.1 (SD ± 4.8) years. Overall NVP plasma levels ranged from 4-44207 ng/mL (median 6213 ng/mL, IQR 3097–8606.5 ng/mL). There were 105 (25.5%) participants with NVP levels of <3100 ng/mL, associated with poor viral suppression. Multivariate linear regression analysis showed CYP2B6 516 G>T polymorphism (β 0.71, 95% CI 0.4–0.98; p<0.0001), male gender (β 0.45, 95% CI 0.01–0.9; p=0.047) and presence of HIV drug-resistant virus (β 1.98, 95% CI 1.24–2.72; p<0.001) were the independent factors influencing NVP plasma concentration.

Conclusions: The majority of patients receiving an NVP-based ART regimen had plasma concentrations within the therapeutic range. CYP2B6 516 G>T polymorphism, gender and presence of a HIV drug-resistant mutation significantly influences NVP plasma concentration. Routine pharmacogenetic testing and measurement of NVP plasma
concentrations, considering gender and presence of HIV drug-resistant mutations are key to ensuring optimal ART treatment outcomes in Kenya.

**Keywords**
Nevirapine plasma concentration, pharmacogenetics and clinical parameters, HIV-1 patients in Kenya
Background

The use of antiretroviral therapy (ART) is an integral component in reducing the burden of HIV globally. In 2018, it was estimated that 68% (826,000) of adults and 73% (71,500) of children in Kenya needing ART were actually receiving it. A remarkable scale up of ART has put Kenya on track to reach the target of AIDS-related deaths. Kenya is among the countries that have adopted the 2015 World Health Organization (WHO) recommendations, which require immediate initiation of ART to people diagnosed with HIV, aimed at increasing ART access further. At the time of the study, the first-line ART guidelines for children, youth and adults in Kenya typically contained a backbone of two nucleoside reverse transcriptase inhibitors (NRTIs; zidovudine [AZT], stavudine [d4T], tenofovir [TDF] or lamivudine [3TC]), plus one non-nucleoside reverse transcriptase inhibitor (NNRTI): either nevirapine (NVP) or efavirenz (EFV).

NVP is a particularly extensively prescribed antiretroviral drug in developing countries mainly because of its efficacy, availability, low cost and use in prevention of vertical HIV transmission. However, a higher incidence of rashes (which can be severe and life-threatening, such as Stevens-Johnson syndrome) associated with NVP, the association with a rare but potentially life-threatening risk of hepatotoxicity and a low genetic barrier to resistance are the fundamental factors that restrict the use of NVP. A study in Kenya reported that 35% of patients on NVP experienced treatment failure. Factors such as unavailability of ART stock, poor prescribing practice and prompt antiretroviral refill are known to significantly affect treatment outcomes.

Generally, the most important aspect of ART management is ideal drug exposure; extensive use of, or suboptimal exposure to, ART, especially NNRTIs (NVP and EFZ), bestows countless risks to the success of treatment. Studies in the USA, Europe and Asia have shown that low NNRTI concentrations are predictive of virologic failure and highly ART drug-resistant HIV quickly develops when administered in suboptimal regimens. In Africa, studies have reported expansive person to person variation in plasma antiretroviral levels among patients with management failure, with a large percentage falling out of the therapeutic window. Though countable reports have shown plasma NVP concentrations affect treatment outcome, therapeutic drug level quantification is currently not part of HIV management in many countries, including Kenya.

NVP is majorly metabolized by cytochrome P450 2B6 (CYP2B6) and minorly by CYP3A isoforms. The occurrence of single-nucleotide polymorphisms (SNPs) especially on 516GT and 983TC, are correlated with significant changes in hepatic enzyme metabolic activities. Other factors such as body weight, age, clinical outcome, gender, CD4 and HIV viral load nadir are also important determinants of NVP plasma levels.

To build up data aimed at personalizing ART treatment in Kenya, this study assessed the relationship between CYP2B6 516G>T and 983T>C polymorphism, HIV drug resistant mutation, and other clinical parameters with NVP concentrations among HIV-1 patients receiving ART treatment in western and coastal Kenya.

Methods

Ethical statement

This study was approved by the Kenya Medical Research Institutes’ (KEMRI) Scientific Review Unit (SERU) (KEMRI/SERU/CVR/002/3214) and NACOSTI (NACOSTI/P/19/11747/28173). Before recruitment in this study, all patients filled in written informed consent for study participation.

Design and study population

This was a cross-sectional study conducted between August 2018 to January 2020 and was part of an ongoing study designed to establish a cost-effective laboratory method to monitor antiretroviral adherence in HIV-1 infected individuals on treatment in Kenya. Patients were recruited in this study if they were: (i) HIV-1 infected adults (aged above 18 years), attending the two HIV treatment programs, (ii) willing to voluntarily give written informed consent, (iii) able to read either English or Kiswahili, (iii) on ARV treatment for 12 months, (iv) be on NVP based 1st line ARV treatment regimen and (v) HIV patients with viral load results at month 12 of treatment. The patients were categorized as either failing (HIV viral load >1000 copies/mL) or responding (HIV viral load <1000 copies/mL) to treatment.

Sample size and recruitment

Using the case control sample size formula described by Lemeshow et al., and using the previous study of Ahsoua et al., which showed that among HIV patients with virological failure at month 12, 12.8% of them developed sub-optimal drug level/drug resistance. In this study, we wished to have a 90% chance of detecting an odds ratio significantly different from 1 at the 5% level. Considering an odds ratio of 2 as an important difference between the two groups, a total of 376 (188 cases and 188 controls) were to be recruited from each of the two sites. A two-stage sampling method was then used to select patients meeting the inclusion criteria from the two sites. First, the overall number of patients meeting the inclusion criteria was generated based on the laboratory records. A total of 272 patients from Kisumu (western Kenya) and 105 patients from Malindi (costal Kenya) were then selected based on probability proportionate to size. Second, a consecutive sampling technique was used to obtain consent from and recruit every patient meeting the inclusion criteria until the required sample size was achieved.

Data collection

An exhaustive structured interview (including demographic data, clinical history, adherence, HIV stigma and medical history) was used to collect patient-related information (see Extended data). These interviews were conducted by medical clinician or doctor employed by the two organizations and who regularly attends to these patients. Each interview was conducted in a separated private room and lasted for about 45 minutes.
After the interviews, the patients were sent to the phlebotomy room where blood specimens were drawn by a trained phlebotomist into ethylenediaminetetraacetic acid (EDTA)-containing Vacutainers® (BD, US) for determination of NVP plasma concentration and CYP2B6 516G>T and 983T>C genetic analysis. From each of the patients, approximately 5ml of intravenous blood was collected in EDTA tubes. Blood samples were centrifuged at 20,000g to collect plasma, which was stored at -20°C at each research site until it was shipped in dry ice to the KEMRI Nairobi laboratory for storage and laboratory testing.

The plasma HIV-1 RNA

RNA was extracted manually from 1ml of all HIV-1 samples using QIAamp viral RNA mini kit (Cat. No. 52906, Qiagen Inc., USA) according to the manufacturer instructions. Purified RNA was eluted in 60μL of molecular grade water. A volume of 10μL of RNA extract was used for quantification with the Generic HIV Viral Load assay (Biocentric, Bandol-France). The cycling conditions comprised of 50°C for 10 minutes and 95°C for 5 minutes, followed by 50 cycles of 95°C for 15 seconds and 60°C for 1 minute. Amplification and data acquisition were carried out using the ABI Prism 7300 Sequence Detection System (Applied Biosystems) and the detection cut-off value was 60 HIV-1 RNA copies/ml.

NVP plasma concentrations

The NVP plasma concentrations were measured using a Xevo TQ-S tandem quadrupole mass spectrometer (Waters Corporation, U.S.A.) designed for ultra-high performance as described by Reddy et al.22. First, the HIV virus was inactivated as follows. Into a 1.5ml Eppendorf tube, 50μl of plasma and 5μl internal standard (2μg/ml nevirapine, purity: 100 %, from Vivan Life Sciences, Mumbai, India prepared in methanol) was added. This was heated at 65°C for 10 minutes, followed by 10 minutes cooling at room temperature. 100μl cold methanol (-20°C) was then added to each sample and kept at -20°C for 10 minutes. This was followed by eight minutes of centrifugation at 20,000g. 20°C to collect the supernatant in a clean 1.5ml tube. Then, 850μl ammonium acetate buffer (pH = 3.00) was added to the supernatant and briefly centrifuged. The sample was considered safe to be handled in a non P3 laboratory.

Solid phase extraction was carried out using Bond Elut C18 cartridges. The cartridges were prepared and placed onto the Visiprep Vacuum Manifold with standard lid (Merck, Germany). The Bond Elute C18 150×4.6mm, 5μm column was conditioned by first passing through 1ml methanol, followed by 1ml ultrapure water. Each column was then charged with 150μl samples containing 850μl ammonium acetate buffer (pH = 3.00), followed by twice cleaning using 1ml ultrapure water. The first cleaning was collected into clean separate tube while the second water cleaning collected in the waste tubes. The columns were vacuum dried (5–10 kPa). NVP elution was carried out at a flow rate of 1ml/min twice using 500μl methanol with vacuum drying between the two elutions. Elutes were then completely evaporated using Thermo Scientific™ Reacti-Vap™ Evaporators (Thermo Fisher Scientific Inc, USA) at 37°C for 30 minutes. This was then reconstituted using 100μl of equal parts 1:1 acetonitrile and water, vortexed briefly and transferred into 50ml capped vials and placed into the Xevo TQ-S for quantification. Approximately 1μl of the samples was injected automatically into the LC/MS/MS instrument and quantified within five minutes. NVP plasma concentration was categorized as <3100 ng/mL (below therapeutic range), 3100–4300 ng/mL (therapeutic range) and >4300 ng/mL (above therapeutic range) as previously defined.23.

CYP2B6 genotyping

DNA was extracted from patients’ blood samples using the QIAamp DNA Blood Mini Kit (Cat. No. 51106, Qiagen GmbH, Hilden, Germany) according to the manufacturer’s instructions. Briefly, 20μl QIAGEN Protease and 200μl blood sample were added into a 1.5ml microcentrifuge tube and 200μl of Buffer AL added and mixed by pulse-vortexing for 15 seconds. This was incubated at 56°C for 10 minutes. This was followed by a series of washing and eventually the DNA was eluted using 200μl Buffer AE at 6000 × g (8000 rpm) for one minute. The quality of DNA was measured using a ND-1000 UV spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Genotyping was carried out on an ABI 7500 Fast Sequence Detection System (Applied Biosystems, Foster City, CA, USA). SNPs were analyzed using the validated Taqman Genotyping Assays for CYP2B6 516G>T (rs3745274; assay ID C_7817765_60) and CYP2B6 983T>C (rs28399499; assay ID C_60732328_20), according to the manufacturer’s instructions. Briefly, in a final volume for each reaction of 25μl, consisting of 2x TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 20x drug metabolizing genotype assay mix and 10ng genomic DNA. The PCR profile consisted of an initial step at 50°C for 2 minutes and 50 cycles at 95°C for 10 minutes and 92°C for 15 seconds. The plates were read using the allelic discrimination settings. The SNP assay was set up using SDS, version 1.3.0 as an absolute quantification assay. Post-assay analysis was done using SDS software. The results for CYP2B6 516G>T and 983T>C genotypes were defined as follows: homozygous wild type as 516GG or 983TT, heterozygous as 516GT or 983TC, and homozygous mutated as 516TT or 983CC.

HIV drug-resistant genotyping

The presence of HIV drug-resistant mutation was tested using an in-house genotypic method previously described Lehman et al.24. This involved the following steps:

RNA extraction. The viral RNA was extracted from plasma using QIAamp Viral RNA Extraction Kit (Cat. No. 52906, Qiagen Inc., USA) according to manufacturer’s instructions.

Nested PCR amplification and visualization. A nested PCR was then performed using AmpliTaq Gold (Roche Molecular Systems, Branchburg, NJ). Briefly, in the first round; HIV-1 pol gene was amplified using primers (RT18: 5’ GGAAACCTGGATTTCTGCTATTAAGTCTTTTGATGGG 3’ and RT21: 5’ CTGGATTTCGCTATTAGGTCTTTGAGG 3’) achieved as follows: one cycle of 45°C for one minute and 94°C for two
minutes, followed by 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for one minute, with a final extension of 72°C for two minutes, and 72°C for one minute, with a final extension of 72°C for 10 minutes. The PCR amplification was confirmed by visualization with ethidium bromide staining of agarose gel. The nested reverse transcription-polymerase chain reaction (RT-PCR) amplified a positive sample of 645 base pairs.

**BigDye sequencing reactions.** The PCR positive samples were first cleaned to remove excess primers and nucleotides in a single step using ExoSAP-IT™ PCR technology (Cat. No. 78200, Applied Biosystems, Foster City, CA, USA). Briefly, for each positive PCR product visualized on the gel, 5ul of the PCR product was mixed with 2ul ExoSAP-IT reagent and held at 37°C for 15 minutes, followed by 80°C for 15 minutes in a thermocycler.

The cleaned DNA was then amplified using a BigDye Terminator Kit (Cat. No. 4337457, Applied Biosystems, Foster City, CA, USA) and an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, US). Briefly, a 10ul reaction comprising 5.5ul DNA grade water, 2ul 5x BigDye buffer, 1ul BigDye 0.5ul primers (RT 1: 5′ CCAAAGTTAACAATGGCCATTGACAGA 3′ and RT4: 5′ AGTTCTATAACCCATCAAAG 3′) was achieved as follows: one cycle of 94°C for two minutes and 30 cycles of 94°C for 10 seconds, 55°C for 30 seconds, and 72°C for one minute, with a final extension of 72°C for 10 minutes. The PCR amplification was confirmed by visualization with ethidium bromide staining of agarose gel. The nested reverse transcriptase-polymerase chain reaction (RT-PCR) amplified a positive sample of 645 base pairs.

**Drug resistant interpretation.** The ART drug resistance mutations were identified using the Stanford University and International AIDS Society-USA website. Genotypic resistance was defined as the presence of resistance mutations associated with impaired drug susceptibility using the Stanford Genotypic Resistance Interpretation Algorithm.

**Data analysis**

Frequencies and percentages were used to present the socio-demographic data. The relationship between NVP plasma concentrations and CYP2B6 516G>T and 983T>C and the presence of HIV drug-resistant mutations were determined using Kruskal-Wallis test and Dunn’s test. Univariate and multivariate linear regression analyses were performed to determine the relationship between NVP plasma concentrations and genetic polymorphisms, presence of HIV drug-resistant mutations and other clinical characteristics at the significance level of p<0.05. All statistical analyses were performed using STATA v 13 (StataCorp LP, Texas, USA).

**Results**

**Baseline characteristics**

The results from the 377 patients were assessed, of whom 272 (72.2%) were from Kisumu county (western Kenya), 223 (59.2%) were female and 114 (30.2%) had a HIV viral load >1000 copies/mL. The median age of the patients was 41 years (IQR = 34–49 years), with a median duration of living with HIV infection of five years (IQR = 1–11 years) and a median duration since ART initiation of three years (IQR = 1–8 years). There were 306 (81.2%) patients currently taking lamivudine, nevirapine, tenofovir regimen, while 97 (25%) had missed an ART scheduled visit due to HIV-related illness and 205 (54.4%) reporting missing taking current ART at least once (Table 1).

**NVP plasma concentration**

The steady-state NVP plasma concentrations varied widely among patients, ranging from 4 ng/mL to 44,207 ng/mL (median 5179 ng/mL, IQR = 2557–7453 ng/mL). Out of the total 377 patients, 96 (25.5%) had an NVP concentration <1000 ng/mL and 26 (6.9%) had an NVP concentration of 3100–4300 ng/mL, with the majority, 255 (67.6%), of the patients having an NVP concentration >4300 ng/mL (Table 2). No significant differences were found with regards to region of origin between patients with NVP levels <1000 ng/mL and those with NVP levels of 3100–4300 ng/mL or >4300 ng/mL (p=0.829). Further, no differences were observed with regards to gender, HIV RNA viral load, age and duration infected with HIV in patients with NVP levels >4300 ng/mL when compared to patients with lower NVP levels. Similarly, no significant correlations were observed with regards to age of sexual debut (p = 0.785), duration since ART initiation (p=0.888), initial ART regimen type (p=0.883), current ART regimen type (p=0.972), missing scheduled HIV care visit (p=0.644), or non-adherence to current ART regimen (p=0.769) in patients with NVP levels >4300 ng/mL when compared to patients with lower NVP levels (Table 1).

**Prevalence of CYP2B6 516G>T and 983T>C genotypes**

The number of patients with GG, GT and TT genotypes for the CYP2B6 516G>T SNP were 142 (37.7%), 187 (49.6%) and 48 (12.7%), respectively. In the case of the CYP2B6 983T>C SNP, the majority of patients (n = 326, 86.5%) had the homozygous wild type TT genotype. There were 48 patients (12.7%) who had the heterozygous mutant TC genotype, while three (0.7%) patients had the homozygous mutant CC genotype.

**Relationship between CYP2B6 516G>T and 983T>C genotypes, HIV drug-resistant mutation and plasma NVP levels**

In this study, CYP2B6 516G>T and 983T>C SNPs were correlated with increased mean NVP plasma concentrations (Table 2). For CYP2B6 516G>T, patients who had the homozygous mutation (CYP2B6 516TT) had higher median
### Table 1. Patients’ characteristics and distribution according to nevirapine plasma levels.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Nevirapine plasma concentration</th>
<th>Overall</th>
<th>&lt;3100ng/mL</th>
<th>3100 - 4300ng/mL</th>
<th>&gt;4300ng/mL</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Sub-therapeutic range</td>
<td>Therapeutic range</td>
<td>Above therapeutic range</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>96 (25.5%)</td>
<td>26 (6.9%)</td>
<td>255 (67.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Region, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kisumu (western Kenya)</td>
<td></td>
<td>272 (72.2)</td>
<td>68 (70.8)</td>
<td>20 (76.9)</td>
<td>184 (72.2)</td>
<td>0.828</td>
</tr>
<tr>
<td>Malindi (coastal Kenya)</td>
<td></td>
<td>105 (27.8)</td>
<td>28 (29.2)</td>
<td>6 (23.1)</td>
<td>71 (27.8)</td>
<td></td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td>223 (59.2)</td>
<td>60 (62.5)</td>
<td>18 (69.2)</td>
<td>145 (56.9)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>154 (40.8)</td>
<td>36 (37.5)</td>
<td>8 (30.8)</td>
<td>110 (43.1)</td>
<td>0.351</td>
</tr>
<tr>
<td>HIV-RNA copies/mL, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;1000 copies/mL</td>
<td></td>
<td>114 (30.2)</td>
<td>34 (35.4)</td>
<td>10 (38.5)</td>
<td>70 (27.5)</td>
<td>0.224</td>
</tr>
<tr>
<td>&lt;1000 copies/mL</td>
<td></td>
<td>263 (69.8)</td>
<td>62 (64.6)</td>
<td>16 (61.5)</td>
<td>185 (72.5)</td>
<td></td>
</tr>
<tr>
<td>Age (years), median (IQR)</td>
<td></td>
<td>41 (34 - 49)</td>
<td>40 (33.5 - 47.5)</td>
<td>41.5 (32 - 52)</td>
<td>42 (35 - 50)</td>
<td>0.73</td>
</tr>
<tr>
<td>Duration with HIV (years), median (IQR)</td>
<td></td>
<td>5 (1 - 11)</td>
<td>4.5 (1 - 12)</td>
<td>4 (1 - 8)</td>
<td>5 (1 - 11)</td>
<td>0.451</td>
</tr>
<tr>
<td>Age of sexual debut (years), median (IQR)</td>
<td></td>
<td>18 (16 - 20)</td>
<td>18 (16 - 19)</td>
<td>17.5 (17 - 20)</td>
<td>18 (16 - 20)</td>
<td>0.785</td>
</tr>
<tr>
<td>Duration since ART initiation (years), median (IQR)</td>
<td></td>
<td>3 (1 - 8)</td>
<td>3 (1 - 8.5)</td>
<td>3 (1 - 6)</td>
<td>4 (1 - 9)</td>
<td>0.888</td>
</tr>
<tr>
<td>Initial ARV type, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>lamivudine, nevirapine, stavudine</td>
<td></td>
<td>59 (15.6)</td>
<td>11 (11.5)</td>
<td>5 (19.2)</td>
<td>43 (16.9)</td>
<td></td>
</tr>
<tr>
<td>lamivudine, nevirapine, zidovudine</td>
<td></td>
<td>62 (16.4)</td>
<td>16 (16.7)</td>
<td>2 (7.7)</td>
<td>44 (17.3)</td>
<td></td>
</tr>
<tr>
<td>lamivudine, nevirapine, tenofovir</td>
<td></td>
<td>40 (10.6)</td>
<td>11 (11.5)</td>
<td>3 (11.5)</td>
<td>26 (10.2)</td>
<td>0.883</td>
</tr>
<tr>
<td>lamivudine, efavirenz, tenofovir</td>
<td></td>
<td>180 (47.7)</td>
<td>49 (51)</td>
<td>13 (50)</td>
<td>118 (46.3)</td>
<td></td>
</tr>
<tr>
<td>lamivudine, efavirenz, zidovudine</td>
<td></td>
<td>36 (9.5)</td>
<td>9 (9.4)</td>
<td>3 (11.5)</td>
<td>24 (9.4)</td>
<td></td>
</tr>
<tr>
<td>Current ARV type, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>lamivudine, nevirapine, stavudine</td>
<td></td>
<td>4 (1.1)</td>
<td>1 (1)</td>
<td>0</td>
<td>3 (1.2)</td>
<td></td>
</tr>
<tr>
<td>lamivudine, nevirapine, zidovudine</td>
<td></td>
<td>67 (17.8)</td>
<td>19 (19.8)</td>
<td>4 (15.4)</td>
<td>44 (17.3)</td>
<td>0.954</td>
</tr>
<tr>
<td>lamivudine, nevirapine, tenofovir</td>
<td></td>
<td>306 (81.2)</td>
<td>76 (79.2)</td>
<td>22 (84.6)</td>
<td>208 (81.6)</td>
<td></td>
</tr>
<tr>
<td>Missed ART scheduled visit, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>97 (25.7)</td>
<td>28 (29.2)</td>
<td>7 (26.9)</td>
<td>62 (24.3)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>280 (74.3)</td>
<td>68 (70.8)</td>
<td>19 (73.1)</td>
<td>193 (75.7)</td>
<td>0.644</td>
</tr>
<tr>
<td>Missed taking current ART, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>205 (54.4)</td>
<td>51 (53.1)</td>
<td>16 (61.5)</td>
<td>138 (54.1)</td>
<td>0.769</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>172 (45.6)</td>
<td>45 (46.8)</td>
<td>10 (38.5)</td>
<td>117 (45.8)</td>
<td></td>
</tr>
</tbody>
</table>

ARV, antiretroviral; ART, antiretroviral therapy.
NVP plasma levels (6753.5 ng/mL, IQR 4595.5–11046 ng/mL), as did those who were heterozygous for the mutation (CYP2B6 516GT; 5579 ng/mL, IQR 2960–8323 ng/mL), compared to those with the wild-type (CYP2B6 516GG; 3920.5 ng/mL, IQR 1416–6278 ng/mL) (p<0.0001). In the case of CYP2B6 983T>C, although the median NVP plasma concentrations were higher among patients who had the heterozygous genotype (CYP2B6 983TC; 5987 ng/mL, IQR 3101.5–9143 ng/mL) than those who had homozygous wild-type (CYP2B6 983TT; 5132 ng/mL, IQR 2394–7384 ng/mL), the distribution was not significant (p=0.33).

With regard to the presence of a HIV drug-resistant mutation, although there were only 31 (8.2%) patients with an NVP-based resistant mutation as opposed to 346 (91.8%) without, the median plasma NVP levels for those with resistant mutations was almost half (2283 ng/mL, IQR 18–5283 ng/mL) that of those without (5498 ng/mL, IQR 2960–7690 ng/mL) (p=0.001) (Table 2). The associations between log_{10}-transformed plasma NVP concentrations and CYP2B6 genotypes and the presence of HIV drug-resistant mutations are shown in Figure 1.

Regression analysis
In the multivariate linear regression model, factors that remained significantly associated with a higher NVP plasma levels included: the T allele of CYP2B6 G516T genotype (adjusted β 0.71, 95% CI 0.4–0.98; p<0.0001), male gender (adjusted β 0.45, 95% CI 0.01–0.9; p=0.047) and presence of drug-resistant virus (adjusted β 1.98, 95% CI 1.24–2.72; p<0.001) (Table 3).

Discussion
In this study, in the two regions of Kenya reporting highest prevalence of HIV infection, we found wide variation in person-to-person NVP concentrations, ranging from 4ng/mL to 44,207 ng/mL (median 5179 ng/mL, IQR 2557–7453 ng/mL). This range is wider compared to other studies reported in Kenya26, in South Africa27 and in India23.

The therapeutic range of NVP plasma concentration is indicated as 3000 to 8000 ng/mL. In our study, the number of participants with plasma NVP levels within this therapeutic range was 255 (67.6%). The NVP plasma concentration required to achieve virologic control is indicated as >3000 ng/mL28. Reports associate NVP plasma concentrations lower than this threshold with poor virologic control and a concomitant increase in the number of NNRTI–resistant mutations29. The current study reports that 25.5% of patients had NVP plasma levels of <3100 ng/mL, associated with poor viral suppression. This prevalence was higher compared to those reported earlier in Kenya26 and in Italy30. This finding may be anticipated among patients with a stable and longer NVP treatment period, with 25% of them reporting non-adherence to medication.

The prevalence of CYP2B6 516T (37.7% GG, 49.6% GT and 12.7% TT) and CYP2B6 983C (86.5% TT, 12.7% TC and 0.7% CC) genotypes among these patients was comparable to those described among other African ethnic groups26,31. Studies have already established the importance of CYP2B6 gene polymorphisms as a key determinant influencing NVP plasma concentrations32,33. In the current study, patients who had both CYP2B6 516G>T and CYP2B6 983T>T genotypes had higher plasma NVP concentrations. This effect was more pronounced among patients who were homozygous for the mutant (CYP2B6 516 TT). Even though this study was cross-sectional, several longitudinal studies have reported a genotype dose-dependent increase in NVP plasma concentration among carriers of the CYP2B6 c.516 T allele26,30,34. For CYP2B6 983T>C, even though there were only 48 and

### Table 2. Plasma nevirapine concentrations by CYP2B6 516G>T and 983T>C genotype and presence of drug-resistant HIV.

<table>
<thead>
<tr>
<th>Variable</th>
<th>N (%)</th>
<th>Geometric mean</th>
<th>Median (IQR)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2B6 516G&gt;T</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homozygous wild type (GG)</td>
<td>142 (37.7)</td>
<td>1422.9</td>
<td>3920.5 (1416 - 6278)</td>
<td></td>
</tr>
<tr>
<td>Heterozygous mutant (GT)</td>
<td>187 (49.6)</td>
<td>2307.1</td>
<td>5579 (2960 - 8323)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Homozygous mutant (TT)</td>
<td>48 (12.7)</td>
<td>6942.8</td>
<td>6753.5 (4595.5 – 11,046)</td>
<td></td>
</tr>
<tr>
<td>CYP2B6 983T&gt;C</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homozygous wild type (TT)</td>
<td>326 (86.5)</td>
<td>2137.6</td>
<td>5132 (2394 - 7384)</td>
<td></td>
</tr>
<tr>
<td>Heterozygous Mutant (TC)</td>
<td>48 (12.7)</td>
<td>2658.5</td>
<td>5987 (3101.5 - 9143)</td>
<td>0.33</td>
</tr>
<tr>
<td>Homozygous Mutant (CC)</td>
<td>3 (0.7)</td>
<td>5018.5</td>
<td>4990 (4607 - 5498)</td>
<td></td>
</tr>
<tr>
<td>HIV drug resistant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>31 (8.2)</td>
<td>510.7</td>
<td>2283 (18 - 5283)</td>
<td>0.001</td>
</tr>
<tr>
<td>No</td>
<td>346 (91.8)</td>
<td>2523.3</td>
<td>5498 (2960 - 7690)</td>
<td></td>
</tr>
</tbody>
</table>
Table 3. Regression analyses of factors associated with nevirapine plasma trough concentrations.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariate analysis</th>
<th></th>
<th>Multivariate analysis</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unadjusted β Lower</td>
<td>Upper 95.0% CI for β</td>
<td>P</td>
<td>Adjusted β Lower</td>
</tr>
<tr>
<td>HIV viral load</td>
<td>0.19 -0.32 0.70</td>
<td>0.473</td>
<td>0.77 0.321</td>
<td>0.26 -0.25 0.75</td>
</tr>
<tr>
<td>Site</td>
<td>-0.08 -0.60 0.44</td>
<td>0.755</td>
<td>0.08 0.752</td>
<td>0.08 -0.42 0.58 0.752</td>
</tr>
<tr>
<td>Age</td>
<td>0.01 -0.01 0.03</td>
<td>0.428</td>
<td>0.02 0.03 0.099</td>
<td>0.02 0.00 0.03 0.099</td>
</tr>
<tr>
<td>Gender</td>
<td>0.39 -0.06 0.84</td>
<td>0.089</td>
<td>0.90 0.047</td>
<td>0.45 0.01 0.90 0.047</td>
</tr>
<tr>
<td>Duration infected with HIV</td>
<td>-0.01 -0.06 0.03</td>
<td>0.517</td>
<td>-0.01 0.03 0.563</td>
<td>-0.01 0.00 0.03 0.563</td>
</tr>
<tr>
<td>Age of sexual debut</td>
<td>0.01 -0.05 0.07</td>
<td>0.803</td>
<td>0.04 0.02 0.09</td>
<td>0.04 0.02 0.09 0.162</td>
</tr>
<tr>
<td>Missed scheduled HIV care visit</td>
<td>-0.03 -0.53 0.46</td>
<td>0.894</td>
<td>0.07 0.56 0.77</td>
<td>-0.03 0.02 0.56 0.77</td>
</tr>
<tr>
<td>Duration since ART initiation</td>
<td>0.01 -0.04 0.07</td>
<td>0.637</td>
<td>0.02 0.03 0.454</td>
<td>0.02 0.00 0.03 0.454</td>
</tr>
<tr>
<td>Initial ART regimen</td>
<td>-0.08 -0.35 0.20</td>
<td>0.575</td>
<td>-0.10 0.37 0.18</td>
<td>-0.10 0.37 0.18 0.493</td>
</tr>
<tr>
<td>Change ART regimen</td>
<td>-0.30 -0.86 0.25</td>
<td>0.278</td>
<td>-0.14 0.66 0.39</td>
<td>-0.14 0.66 0.39 0.613</td>
</tr>
<tr>
<td>Current ART regimen</td>
<td>0.00 -0.34 0.34</td>
<td>0.998</td>
<td>0.07 0.27 0.692</td>
<td>0.07 0.27 0.40 0.692</td>
</tr>
<tr>
<td>Missed current ART regimen</td>
<td>-0.17 -0.64 0.30</td>
<td>0.469</td>
<td>-0.08 0.38 0.728</td>
<td>-0.08 0.06 0.46 0.728</td>
</tr>
<tr>
<td>SNP G516T</td>
<td>0.65 0.33 0.97</td>
<td>&lt;0.0001</td>
<td>0.71 0.98 &lt;0.0001</td>
<td>0.71 0.40 0.98 &lt;0.0001</td>
</tr>
<tr>
<td>SNP T983C</td>
<td>0.21 -0.36 0.79</td>
<td>0.467</td>
<td>0.34 0.22 0.91</td>
<td>0.34 0.22 0.91 0.232</td>
</tr>
<tr>
<td>HIV drug resistant mutation</td>
<td>1.60 0.77 2.43</td>
<td>.006</td>
<td>1.98 1.24 2.72</td>
<td>1.98 1.24 2.72 0.001</td>
</tr>
</tbody>
</table>

ART, antiretroviral therapy; SNP, single nucleotide polymorphism.
three participants with the heterozygous mutant genotype (CYP2B6 983TC) and the homozygous mutant (CYP2B6 983CC), respectively, these genotypes were marked with raised NVP plasma concentrations. In agreement with previous work in Kenya\textsuperscript{38}, which reported that the heterozygous TC genotype was associated with 55% higher NVP levels compared to individuals who had the wild type TT genotype. The SNP in CYP2B6 983T>C results in the variant protein CYP2B6*18 with I328T as the only amino acid change\textsuperscript{37}. In vitro experiments have shown no measurable protein or activity with the expression of CYP2B6 983TC and is thus termed as a null allele\textsuperscript{36}. Therefore, in other studies, the null status of CYP2B6 983TC has been associated with a greater impact compared to the CYP2B6 516GT\textsuperscript{36,34}.

In this study, although there were only 8.2% patients with a HIV drug-resistant mutation to both NNRTIs and NRTIs, compared to 91.8% with susceptible viruses, median plasma NVP levels were almost half that of those who did not have drug-resistant HIV. In agreement with other reports, the presence of a HIV drug-resistant mutation is associated with higher NVP plasma concentrations\textsuperscript{47}. Sustained optimal NVP plasma concentration is vital, given that only a single point mutation at specific position on the HIV-1 pol gene is associated with increased NVP resistance\textsuperscript{48}. Development of HIV drug-resistant strains are shown to occur at the trough plasma NVP concentration of $\leq$3μg/ml, which has been correlated with increased risk of treatment failure\textsuperscript{18,39}.

Beyond genetic background and viral dynamics, other patient pharmacoeological factors influencing the day-to-day concentration of drugs were evaluated. Although not significant, male patients had slightly higher NVP plasma concentrations compared to females, contrary to a report from South Africa\textsuperscript{49}, which showed that females had higher median NVP levels than males. This difference in NVP plasma levels between genders has been attributed to the differences in body size and drug clearance rates between males and females. Older patients had higher median NVP plasma levels than younger ones, although this was not significant. This corresponds to studies that indicated more rapid NVP metabolism among younger children aged $\leq$8 years, who may require higher doses of NVP to achieve the therapeutic concentration\textsuperscript{40,41}.

The importance of ART regimen type, adherence, and duration on ART for the success of HIV treatment and care, although not significant in the current study, has been widely studied\textsuperscript{42,43}. Generally, unstable steady-state levels of NVP have been attributed to poor adherence\textsuperscript{44,45}.

Our study had some limitations worth pointing out. First, due to limited resources available, the study could not recruit a larger number of patients. Second, the use of an NVP-based ART regimen in Kenya and other countries, especially developed countries, has been considerably reduced in the recent past, meaning that this study could be relevant to a restricted number of patients. Third, this study assessed well-known SNPs (CYP2B6 516T and CYP2B6 983C), whose relationship with NVP metabolism has been established. Other SNPs or other regulatory genes could also be important in NVP metabolism. Fourth, the outcomes from one population may not be generalized to other populations due to differences in drug effects between those of different ethnicities and body weights. Fifth, this was a cross-sectional study, which only permitted the description of the relationship between NVP plasma concentrations, patient genetics and a few pharmacoeologic factors and not a causal conclusion. Such outcomes can be confirmed in a longitudinal study.

These limitations notwithstanding, our study, conducted in two regions of Kenya marked by high prevalence of HIV infection, shows the significant role of CYP2B6 polymorphisms in NVP plasma concentrations. NVP plasma concentration is linked to the emergence of NVP-related resistant mutations. Moreover, patient pharmacoeologic factors, such as gender, age and ART adherence, are key in influencing NVP plasma concentration. With the consistent advancement of technical know-how, even in resource-limited settings like Kenya, individualization of ART is today reachable with the use of pharmacogenomics.

Data availability
Underlying data
Figshare: Role of pharmacogenetics and clinical parameters on nevirapine plasma concentration among HIV-1 patients receiving antiretroviral therapy in Kenya. https://doi.org/10.6084/m9.figshare.11977680.v1\textsuperscript{25}

Extended data
Figshare: Role of pharmacogenetics and clinical parameters on nevirapine plasma concentration among HIV-1 patients receiving antiretroviral therapy in Kenya. https://doi.org/10.6084/m9.figshare.12033699\textsuperscript{21}

This project contains the following extended data:
- Copy of participant consent form (DOCX)
- Copy of interview guide (PDF)

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

Acknowledgements
We wish to acknowledge the study patients, all the staff of the respective comprehensive care clinics in the two regions of Kenya. The authors thank the late Brian Khasimwa and Erickson Angira for HIV drug resistant genotyping and drug plasma measurement.


Emmanuel Ndashimye

Department of Microbiology and Immunology, Western University, London, ON, Canada

Mungiria Juster et al., present a manuscript on effect of CYP2B6 polymorphisms as well as social-demographic factors on NVP concentrations among Kenyans on ART. Dolutegravir in combination with NNRTIs is now preferred first-line regimen in Kenya and other low- and middle-income countries. I therefore find the topic not relevant in view of current HIV treatment programs but in addition to current literature. My comments and queries are written below.

Major comments:
- In the multivariate regression analysis, I find some key confounders applicable to study design and patients missing, for instance, the type of combined ART, and drug dosage.
- The sample size determination for the study is not adequately articulated.

Minor comments and queries:
- The background should include the latest 2020 UNAIDS data on HIV in Kenya and a summary of current NVP use if any in era of tenofovir/lamivudine/dolutegravir.
- How adherence to ART was reported by study patients?
- Were factors which could have affected recruitment of the right patients into the study, for instance, rifampicin exposure, body mass index etc. considered?
- It is important to provide a summary of NVP drug resistance mutations observed.
- The web link to Stanford and IAS databases or references should be included in the test.
- Though not very critical, direct sequencing on a subset of samples is advisable to compare with QPCR results.
- The sequences data from HIV resistance assays should be submitted to Genbank.
The last sentence of conclusions for the abstract should be paraphrased considering the current first-line ART recommendations in Kenya and other countries.

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** HIV, SARS-CoV-2

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Reviewer Report 26 May 2020

https://doi.org/10.5256/f1000research.25010.r63456

© 2020 Giacomelli A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Andrea Giacomelli

Department of Biomedical and Clinical Sciences, DIBIC Luigi Sacco, Milan University, Milan, Italy

I have assessed the manuscript by Juster and co-workers assessing the potential role of pharmacogenetics and clinical parameters on nevirapine plasma concentrations in people living with HIV. The study design was cross-sectional and the authors aimed to correlate CYP2B6 c.516 G>T rs3745274 and c.983T>C genotypes with nevirapine plasma concentration in people living with HIV under their first line nevirapine-based antiretroviral regimens. Although the findings of
an association between CYP2B6 c.516 G>T genotype and nevirapine plasma concentration is in line with previous literature reports, the use of nevirapine is becoming less frequent and consequently the generalizability of the results may be limited. Moreover, there are several methodological points that must be fixed.

Major comments:
- The statement regarding the sample size is not clear. Could the authors better explain how they reached their sample size? In fact, if they had a pre-planned sample size, why did they state in the limitation section of the manuscript that the study size is limited?
- How were patients refereed to perform a genotypic test to detect nevirapine drug resistance?
- It’s not stated how the variables have been handled in the linear regression model. Which are the units entered in the model? In the present format the model is not interpretable.
- The authors entered in the linear regression model several variables that are unlikely to be confounders or factors that may influence nevirapine concentration. For example, the use of drug resistance in the model does not make sense because drug resistance does not impact on nevirapine concentration. Moreover, important variables seem to have been missed such as hepatic viruses' coinfection or body weight. Overall, the model presented is not reliable and should be rebuilt by entering variables which have been demonstrated to potentially impact on nevirapine concentration according to the available literature.

Minor comments:
- Please refer to HIV patients by using “people living with HIV”.

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
No

If applicable, is the statistical analysis and its interpretation appropriate?
No

Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.
**Reviewer Expertise:** HIV, Infectious Diseases, SARS-CoV-2.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com